This article was originally published in Pharmaceutical Approvals Monthly
Ramipril receives additional indication Oct. 4 to reduce risk of stroke, myocardial infarction and cardiovascular death. The ACE inhibitor was previously approved for treatment of hypertension and congestive heart failure following myocardial infarction. Altace labeling has been updated to highlight data supporting efficacy in diabetic patients. The diabetic subpopulation of the pivotal study had a 25% reduction in the incidence of cardiovascular events when compared to placeb
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.